Preclinical antibody approach aims to treat type 1 diabetes at its immune source
Seven years ago, Johns Hopkins researchers and their collaborators announced they had found the X cell, a novel immune cell that plays a key role in the development of type 1 diabetes.
A groundbreaking preclinical study at Johns Hopkins University is exploring the potential of a novel antibody derived from a newly discovered immune cell, known as the "X cell," to treat type 1 diabetes. The X cell, which has characteristics of both B and T cells, plays a crucial role in the immune system's response to the autoimmune attack on insulin-producing beta cells in the pancreas.
The researchers, led by principal investigator Abdel-Rahim A. Hamad, have developed an antibody known as x-mAb, which targets and eliminates the 2% of islet-reactive T cells responsible for destroying beta cells. This approach not only addresses the immediate autoimmune response but also aims to restore the immune system's functionality, potentially reversing type 1 diabetes in its early stages.
Unlike current treatments that solely manage blood sugar levels through insulin replacement, this therapy targets the root cause of the disease by preserving the insulin-producing cells and allowing patients to maintain better blood sugar control. Animal studies have shown promising results, indicating that x-mAb can prevent the onset of type 1 diabetes and preserve the function of insulin-producing cells.
However, translating these findings into a human therapy requires further preclinical and clinical validation. The ultimate goal is to provide a curative treatment for type 1 diabetes, eliminating the need for lifelong insulin supplementation and reducing the risk of complications such as kidney damage, vision loss, and cardiovascular disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
